P
Patricia Rayman
Researcher at Cleveland Clinic Lerner Research Institute
Publications - 90
Citations - 5059
Patricia Rayman is an academic researcher from Cleveland Clinic Lerner Research Institute. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 36, co-authored 82 publications receiving 4526 citations. Previous affiliations of Patricia Rayman include National Institutes of Health & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko,Arnold H. Zea,Brian I. Rini,Joanna Ireland,Paul Elson,Peter A. Cohen,Ali Reza Golshayan,Patricia Rayman,Laura S. Wood,Jorge A. Garcia,Robert Dreicer,Ronald M. Bukowski,James H. Finke,James H. Finke +13 more
TL;DR: Sunitinib-based therapy has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immunosuppression and is correlated with reversal of type 1 T-cell suppression.
Journal ArticleDOI
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke,Brian I. Rini,Joanna Ireland,Patricia Rayman,Amy Richmond,Ali Reza Golshayan,Laura S. Wood,Paul Elson,Jorge A. Garcia,Robert Dreicer,Ronald M. Bukowski +10 more
TL;DR: The demonstration that sunitinib improved type-1 T-cell cytokine response in mRCC patients while reducing Treg function provides a basis for the rational combination of sunit inib and immunotherapy in m RCC.
Journal ArticleDOI
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
Baisakhi Raychaudhuri,Patricia Rayman,Joanna Ireland,Jennifer S. Ko,Brian I. Rini,Ernest C. Borden,Jorge A. Garcia,Michael A. Vogelbaum,James H. Finke +8 more
TL;DR: The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population, and increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and M DSC expansion, respectively, in Patients withglioma.
Journal ArticleDOI
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I. Rini,Tanya B. Dorff,Paul Elson,Cristina Suarez Rodriguez,Dale R. Shepard,Laura S. Wood,Jordi Humbert,Linda Pyle,Yu-Ning Wong,James H. Finke,Patricia Rayman,James Larkin,Jorge A. Garcia,Elizabeth R. Plimack +13 more
TL;DR: A subset of patients with metastatic renal-cell carcinoma can safely undergo surveillance before starting systemic therapy and additional investigation is required to further define the benefits and risks of this approach.
Journal ArticleDOI
Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion
Balint Otvos,Daniel J. Silver,Erin E. Mulkearns-Hubert,Alvaro G. Alvarado,Soumya M. Turaga,Mia D. Sørensen,Patricia Rayman,William A. Flavahan,James S. Hale,Kevin Stoltz,Maksim Sinyuk,Qiulian Wu,Awad Jarrar,Sung Hak Kim,Paul L. Fox,Ichiro Nakano,Jeremy N. Rich,Richard M. Ransohoff,James H. Finke,Bjarne Winther Kristensen,M.A. Vogelbaum,Justin D. Lathia +21 more
TL;DR: It is shown that macrophage migration inhibitory factor (MIF) is primarily an indirect promoter of GBM progression, working to suppress immune rejection by activating and protecting immune suppressive MDSCs within the GBM tumor microenvironment.